Navigation Links
HERmark(TM) Assay Results in Metastatic Breast Cancer Presented at the San Antonio Breast Cancer Symposium
Date:12/14/2007

HER2 Homodimer and HER2 Total Protein Assays Validated in CLIA Laboratory

SOUTH SAN FRANCISCO, Dec. 14 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today presented the results of a study detailing the HERmark(TM) Assay's ability to identify metastatic breast cancer patients who are most likely to respond to Herceptin(R). The study results were presented this week at the San Antonio Breast Cancer Symposium. Also this week, Monogram received confirmation from the College of Pathologists (CAP) that the HERmark assays are approved for routine patient testing in Monogram's CLIA certified clinical reference laboratory.

"The results presented today are an important step along the way to clinical validation of HERmark, the first product based on the VeraTag technology platform," said William Young, Monogram chief executive officer. "In addition to the presentation of important clinical data, I am pleased to report today that the HERmark assays have completed their validation process in Monogram's CLIA-certified clinical reference laboratory. The establishment of solid technical validation data and the ability to perform the assays under high-throughput, well controlled conditions will provide a strong basis for commercialization of HERmark after completion of our ongoing clinical studies."

In the study reported today, Monogram analyzed tissue samples from patients with metastatic breast cancer who were treated with Herceptin, having been selected for such treatment by centralized IHC testing. While current testing methods identified all these patients as being appropriate for Herceptin treatment, Monogram's HERmark Assay was able to distinguish separate sub-populations of patients with different clinical o
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
4. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Tapestry Reports Second Quarter 2007 Results
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Walmart (NYSE: WMT ) and Eli Lilly and Company ... affordable insulin option for people with diabetes.   , ... Beginning in mid-September, Lilly,s Humulin ® brand of ... name Humulin ® ReliOn ®, including 10 mL vials of Humulin® ...
... NASHVILLE, Tenn. , June 21 Emdeon Inc. (NYSE: ... payment cycle management solutions, today announced the acquisition of Chapin Revenue ... is a leading technology-enabled provider of hospital-based revenue cycle services including ... , , ...
Cached Medicine Technology:Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 2Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 4Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 5Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 2Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 3Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity 4
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... growth worsens ovarian cancer, but its production can be stifled ... nanoparticle, a research team led by scientists at The University ... Journal of the National Cancer Institute. , "The protein interleukin-8 ... senior author Anil Sood, M.D., professor in the M. D. ...
... Works to Help Hollywood ,Stay Sane in an Insane ... ... Roy, M.A., "The,Industry Therapist" ( http://www.theIndustryTherapist.com ) is asking the,question why the ... Spears, mental illness., "Heath Ledger,s death is being treated with kid ...
... Feb. 26 Hologic, Inc.,(Nasdaq: HOLX ) today ... at the Raymond James & Associates 29th Annual,Institutional Investors ... Grand Cypress Hotel in Orlando, FL., Interested parties ... of,Hologic,s investor presentation on Monday, March 3, 2008 at ...
... clots, study says, , , TUESDAY, Feb. 26 (HealthDay News) ... associated with cancer treatment-related anemia may do more harm ... , The drugs -- erythropoiesis-stimulating agents (ESAs) -- increase ... risk of blood clots known as venous thromboembolisms (VTE) ...
... Increased ... 3.85% and 2.96%, Respectively, MEXICO CITY, Feb. 26 ... one of the leading Mexican,distributors of pharmaceutical products, beauty aids, ... its consolidated financial and operating results for the fourth,quarter of ...
... 26 Schnitzer West announced today,that one of the ... Coast gym in The Shops at The Bravern in ... time to meet the needs of approximately 2,300,Microsoft employees ... of the,project beginning this fall., DavidBartonGym will offer ...
Cached Medicine News:Health News:Researchers identify and shut down protein that fuels ovarian cancer 2Health News:Researchers identify and shut down protein that fuels ovarian cancer 3Health News:Hologic to Present at the Raymond James & Associates 29th Annual Institutional Investors Conference 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 2Health News:Anemia Drugs for Cancer Patients Increase Death Risk 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 2Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 3Health News:Grupo Casa Saba Announces Fourth Quarter 2007 Results 4Health News:World-Famous DavidBartonGym Buffs up the Bravern 2Health News:World-Famous DavidBartonGym Buffs up the Bravern 3
... This unique system uses prolene as thread-guide ... The hollow Ritleng Probe is inserted into the ... fed through it. The probe is then withdrawn ... mm 0.64 mm diam silicone tubing into place. ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... collarette conforms to natural anatomy of ... Pre-loaded on disposable inserter/dilator instrument for ... forceps. The Micro-Large plugs feature the ... natural shape of the eyelid. The ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: